Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).

被引：0
|
作者：
Chang, Lawrence
Hall, Peter S.
Preger, Luciana
Sjekloca, Nikoleta
Bergamaco, Estevan
Broe, Anne
Petrova, Plamena
Berg, Paul
Reich, Adam
Pawar, Neha
Gharaibeh, Mahdi
机构：
[1] Gilead Sci Inc, Foster City, CA USA
[2] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Scotland
[3] Genentech Inc, South San Francisco, CA USA
[4] IQVIA, London, England
[5] IQVIA, Sofia, Bulgaria
[6] IQVIA, La Crosse, WI USA
[7] IQVIA, Gurgaon, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in second line (2L) in the US real-world setting
    Luhn, P.
    O'Hear, C.
    Ton, T. G.
    Hsieh, A.
    Yi, J.
    Chang, C-W
    Funke, R.
    Kurian, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
    Kalinsky, K.
    Spring, L.
    Yam, C.
    Ntalla, I.
    Stwalley, B.
    Sjekloca, N.
    Lai, C.
    Kaushiva, A.
    Taylor, A. J.
    Nanda, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S345 - S346
  • [3] A real-world study of treatment patterns among patients (pts) with metastatic colorectal cancer (mCRC) receiving third-line (3L) or fourth-line (4L) treatment in the US.
    Li, Huichu
    Kopetz, Scott
    Yin, Yu
    Peng, Jianling
    Keenan, Hillary
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 64 - 64
  • [4] Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).
    Amonkar, Mayur
    Gomez-Ulloa, David
    Kothari, Smita
    Cheung, Winson Y.
    Chau, Ian
    Zalcberg, John Raymond
    Lara, Nuria
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [5] Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+in the United States (US)
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Taylor, Aliki
    Sjekloca, Nikoleta
    Kaushiva, Alpana
    Lai, Catherine
    Ntalla, Ioanna
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] HEALTHCARE COSTS AMONG REAL-WORLD PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER (R/MCC) RECEIVING SECOND-LINE (2L) TREATMENT
    Inocencio, T.
    Wu, N.
    Ge, W.
    Gleeson, M.
    Monk, B. J.
    VALUE IN HEALTH, 2022, 25 (07) : S412 - S413
  • [7] PATTERNS OF SECOND-LINE (2L) TREATMENT FOR METASTATIC UROTHELIAL CANCER (MUC) IN CANADA
    Jaffe, D. H.
    DeCongelio, M.
    Li, V. W.
    Lakhdari, K.
    Goulden, S.
    Gooden, K. M.
    VALUE IN HEALTH, 2018, 21 : S41 - S41
  • [8] Treatment patterns and costs in second-line (2L) metastatic colorectal cancer (mCRC)
    Teitelbaum, April H.
    Evans, Dana
    Yu, Elaine
    Morlock, Robert
    Byfield, Stacey DaCosta
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [9] TREATMENT PATTERNS OF SECOND-LINE (2L) METASTATIC UROTHELIAL CANCER (MUC) IN SPAIN
    Clark, O. A.
    Jaffe, D.
    DeCongelio, M.
    Li, V. W.
    Goulden, S.
    Gonzalez, P.
    Gooden, M.
    VALUE IN HEALTH, 2017, 20 (09) : A473 - A473
  • [10] Longitudinal treatment patterns and adverse events (AEs) in younger patients (Pts) with metastatic triple-negative breast cancer (mTNBC): A real-world landscape analysis.
    Kuderer, Nicole Maria
    Varghese, Della
    Hill, Kala
    Lyman, Gary H.
    Botteman, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345